The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Effects of Sacubitril/Valsartan Compared to Olmesartan on the Blood Pressure and Glucolipid Metabolism in DM Patients with Primary Hypertension
Authors
Keywords
-
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-13
DOI
10.1007/s10557-023-07509-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study
- (2022) Hiromi Rakugi et al. HYPERTENSION RESEARCH
- Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction
- (2022) Hasan Ali Barman et al. CLINICAL DRUG INVESTIGATION
- Long Term Metabolic Effects of Sacubitril/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study
- (2022) Giuseppe Armentaro et al. Frontiers in Physiology
- Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis
- (2021) Gonçalo Martins e Pereira et al. Expert Opinion On Drug Safety
- Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension
- (2021) Bin Zhou et al. Nature Reviews Cardiology
- The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
- (2021) Su-Kiat Chua et al. Journal of Clinical Medicine
- Effects of LCZ696 on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials
- (2020) Qiang Geng et al. CARDIOLOGY
- Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry
- (2019) Kornelia Kotseva et al. European Journal of Preventive Cardiology
- New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism
- (2019) Stephanie Eid et al. DIABETOLOGIA
- Effect and safety of LCZ696 in the treatment of hypertension
- (2019) Qiongqiong Li et al. MEDICINE
- Hypertension with diabetes mellitus complications
- (2018) Daisuke Yamazaki et al. HYPERTENSION RESEARCH
- Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study
- (2018) Deanna G. Cheung et al. Journal of Clinical Hypertension
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
- (2018) Paul K. Whelton et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond
- (2018) Kazuomi Kario Current Cardiology Reports
- Hypertension
- (2018) Suzanne Oparil et al. Nature Reviews Disease Primers
- Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double‐blind, 8‐week study
- (2018) Yong Huo et al. Journal of Clinical Hypertension
- The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study
- (2017) Roland E Schmieder et al. EUROPEAN HEART JOURNAL
- Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and HypertensionNovelty and Significance
- (2017) Stefan Engeli et al. HYPERTENSION
- Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
- (2017) Yan Zheng et al. Nature Reviews Endocrinology
- Angiotensin II Receptor–Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
- (2017) Takunori Seki et al. Journal of the American Heart Association
- Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
- (2017) Jelena P Seferovic et al. Lancet Diabetes & Endocrinology
- Global Disparities of Hypertension Prevalence and ControlClinical Perspective
- (2016) Katherine T. Mills et al. CIRCULATION
- Diabetes mellitus and hypertension
- (2016) Ahmet Afşin Oktay et al. CURRENT OPINION IN CARDIOLOGY
- Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension
- (2016) Ouppatham Supasyndh et al. HYPERTENSION RESEARCH
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
- (2016) Dena Ettehad et al. LANCET
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle
- (2012) Erik J. Henriksen et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The renin–angiotensin–aldosterone system and glucose homeostasis
- (2011) James Matthew Luther et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cardiovascular Therapies and Associated Glucose Homeostasis
- (2009) Rhonda M. Cooper-DeHoff et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started